| 0.3801 -0.039 (-9.28%) | 12-08 15:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.53 | 1-year : | 0.62 |
| Resists | First : | 0.45 | Second : | 0.53 |
| Pivot price | 0.36  |
|||
| Supports | First : | 0.34 | Second : | 0.28 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.35 |
| MA(100) : | 0.46 |
MA(250) : | 0.73 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 61.7 |
D(3) : | 65.7 |
| RSI | RSI(14): 52.6 |
|||
| 52-week | High : | 2.28 | Low : | 0.26 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NXL ] has closed below upper band by 42.9%. Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.42 - 0.42 | 0.42 - 0.42 |
| Low: | 0.38 - 0.38 | 0.38 - 0.38 |
| Close: | 0.38 - 0.38 | 0.38 - 0.38 |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Mon, 16 Oct 2023
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer ... - GlobeNewswire
Mon, 07 Aug 2023
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp ... - GlobeNewswire
Thu, 03 Aug 2023
Nexalin's CEO Mark White to be Interviewed Live on “The Big - GlobeNewswire
Mon, 10 Jul 2023
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research ... - GlobeNewswire
Thu, 01 Jun 2023
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization ... - Yahoo Finance
Mon, 27 Mar 2023
Nexalin Technology Provides 2022 Year-End Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 5.7e+006 (%) |
| Held by Institutions | 23.3 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.79e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 17.5 % |
| Return on Equity (ttm) | -46.9 % |
| Qtrly Rev. Growth | 128640 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 4.26 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 37010 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|